Compare Meta Platforms Inc (META) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Neurocrine Biosciences Inc — how do they compare? Meta Platforms Inc trades at $647.51 (market cap $1.64T), while Neurocrine Biosciences Inc trades at $178.67 (market cap $17.40B). The key difference: Meta Platforms Inc is far larger — about 94.3× Neurocrine Biosciences Inc's market cap, and Meta Platforms Inc pays a 0.33% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| META | NBIX | |
|---|---|---|
Market Cap | $1.64T | $17.40B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $180.55 |
52-Week Low | $525.72 | $123.10 |
Enterprise Value | $1.65T | $16.49B |
Dividend Yield | 0.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META stock trades at $653.33, up 1.13% in the last session, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $10.44 versus $6.70 expected. Revenue grew to $201.0 billion in 2025, with a net income margin of 30.08%. Recent news highlights the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, driving positive sentiment.
Outlook remains positive with a consensus price target of $817.32, implying 25% upside. Key opportunities include AI monetization and sustained revenue growth, while risks involve regulatory lawsuits and high capital expenditures. Analyst consensus is strongly bullish with 79% buy ratings, but investors should monitor legal developments and competitive pressures in the social media and AI sectors.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
